Is BriaCell Therapeutics Corp. (BCTXW) a Buy, Sell, or Hold?
NASDAQ : BCTXW
BriaCell Therapeutics Corp.
$0.00089999999 USD
$0.0 (-0.0%)
- Volume
- 186.08K
- Average Volume
- 71.38K
- Market Capitalization
- $1.7K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.06
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.07
Company Overview
NASDAQ
William V. Williams
Biotechnology
Healthcare
BCTXW
16
CA
USD
Liquidity Metrics
0.00
7.07
7.07
1.92
0.00
Sales & Valuation
-$
0.00
0.00
0.00
-3.40
Profitability
-$62.95
-$26.63M
0.00%
0.00%
-142.91%
-112.77%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-4.72
2/9
$21.8M
$27.07M
$3.66M
$10.31M
Key Metrics (TTM)
-$6.88M
0.00
-0.66
7.07
-142.91%
-71.22%
-467817.16%
-1453330.74%
0 days
Company Executives
| Name | Title |
|---|---|
| William V. Williams | Chief Executive Officer, President & Director |
| Gadi Levin | Chief Financial Officer & Corporate Secretary |
| Charles Louis Wiseman FACP | Founder, Principal Research Advisor & Member of Scientific Advisory Board |
| Miguel A. Lopez-Lago | Chief Scientific Officer |
| Giuseppe Del Priore | Chief Medical Officer |
Poll Results
No votes yet today — be the first to share your view!
About BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Stock
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, currently in Phase 3, dedicated to revolutionizing cancer treatment through its innovative cellular immunotherapies. Its flagship product, Bria-IMT, is currently undergoing a pivotal Phase 3 clinical trial for advanced breast cancer, where it's being evaluated in combination with an immune checkpoint inhibitor. Beyond this lead candidate, the company is also advancing the development of personalized, off-the-shelf treatments designed to combat breast, prostate, and various other forms of cancer. Furthermore, BriaCell maintains a strategic partnership with Incyte Corporation, focused on further evaluating Bria-IMT in combination therapies. The company's operations are headquartered in West Vancouver, Canada. ...
Frequently Asked Questions
-
What is the current BriaCell Therapeutics Corp. (BCTXW) stock price?
-
BriaCell Therapeutics Corp.(NASDAQ:BCTXW) stock price is $0.00089999999 in the last trading session. During the trading session, BCTXW stock reached the peak price of $0.0645 while $0.0006 was the lowest point it dropped to. The percentage change in BCTXW stock occurred in the recent session was --0.0% while the dollar amount for the price change in BCTXW stock was -$0.0.
-
BCTXW's industry and sector of operation?
-
The NASDAQ listed BCTXW is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BCTXW?
-
William V. Williams | Chief Executive Officer, President & Director
Gadi Levin | Chief Financial Officer & Corporate Secretary
Charles Louis Wiseman FACP | Founder, Principal Research Advisor & Member of Scientific Advisory Board
Miguel A. Lopez-Lago | Chief Scientific Officer
Giuseppe Del Priore | Chief Medical Officer -
How many employees does BCTXW have?
-
Number of BCTXW employees currently stands at 16. BCTXW operates from Bellevue Centre, West Vancouver, BC V7T 2X1, CA.
-
Link for BCTXW official website?
-
Official Website of BCTXW is: https://briacell.com
-
How do I contact BCTXW?
-
BCTXW could be contacted at phone #604 921 1810 and can also be accessed through its website. BCTXW operates from Bellevue Centre, West Vancouver, BC V7T 2X1, CA.
-
How many shares of BCTXW are traded daily?
-
The average number of BCTXW shares traded daily for last 3 months was 71.38K.
-
What is the market cap of BCTXW currently?
-
The market value of BCTXW currently stands at $1.7K with its latest stock price at $0.00089999999